M1FG
CRSP icon

Mach-1 Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Mach-1 Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,037
Closed -$441K – 114
2023
Q4 		$441K Buy
+7,037
New +$389K 0.17% 145

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mach-1 Financial Group's CRSP Position: Q1 2024 in Review

Mach-1 Financial Group sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 7,037 shares — an estimated $441K sold.

Mach-1 Financial Group first reported a position in CRSP in Q4 2023 and held it in 1 quarter. The position peaked at $441K in Q4 2023. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Mach-1 Financial Group reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 7,037 CRISPR Therapeutics shares in Q1 2024, an estimated $441K.
  • Mach-1 Financial Group first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's CRISPR Therapeutics position peaked at $441K in Q4 2023.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.